<p>成功驾驭股市需要耐心和长期的视角。关键在于坚持一致的计划，并定期向退休账户做出贡献，让复利的力量随着时间的推移发挥其魔力。</p>
<p>然而，寻找潜在的多倍收益股票无疑具有吸引力。那些拥有颠覆性创新的公司，其股票可能正处于快速增长的边缘，能够为股东带来改变生活的回报，这让人着迷。</p>
<p><strong>Recursion Pharmaceuticals</strong>（RXRX -0.98%）是一家临床阶段的生物科技公司，可能具备这样的潜力。该公司利用人工智能（AI）进行药物发现，承诺将彻底改变医学。让我们探讨一下购买该股票是否最终能帮助你成为百万富翁。</p>
<h2>AI 驱动的生物科技</h2>
<p>Recursion 迅速确立了自己在 AI 驱动生物科技领域的领导地位。该公司的 BioHive-2 超级计算机，采用 <strong>Nvidia</strong> AI 芯片，是全球最强大的加速计算系统之一。</p>
<p>通过先进的机器学习技术，BioHive-2 分析大量生物数据，以识别药物靶点，包括与疾病相关的蛋白质和基因。Recursion 的操作系统（OS）评估数百万种化合物，以识别潜在的药物候选者，同时预测药物分子的特性和最佳患者群体，以增强药物设计。</p>
<p>这些努力使得对各种疾病的治疗研究得以加速，同时与传统方法相比降低了成本。</p>
<p>Recursion 今年的一项重大进展是与另一家专注于基于 AI 药物发现的生物科技公司 Exscientia 的合并。Exscientia 在先进化学设计方法方面的专业知识与 Recursion 的生物驱动方法相辅相成。这一结合创造了一个垂直整合的平台，使公司在根本上更强大。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>有前景的治疗候选药物管线</h2>
<p>好消息是，Recursion 的技术已经取得了令人鼓舞的成果，拥有一条强大的药物候选管线，现在还包括 Exscientia 的遗留项目。</p>
<p>其中最有前景的候选药物之一是 REC-994，它可能成为治疗症状性脑血管畸形（CCM）的首个口服疗法，这是一种目前没有任何批准治疗的脑出血疾病。</p>
<p>REC-617 也显示出令人鼓舞的结果，最近的 1 期中期研究表明，在治疗晚期实体瘤方面患者反应积极且耐受性良好。公司认为该药物具有 “最佳同类” 潜力，这是使 Recursion 成为投资者引人注目的机会的几个原因之一。</p>
<p>展望 2025 年，市场将密切关注临床结果和监管更新，作为 Recursion 股票的催化剂：</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA"/></p>
<p>来源：Recursion Pharmaceuticals。</p>
<h2>谨慎的理由</h2>
<p>看起来至少有一个 Recursion Pharmaceuticals 的候选药物最终可能获得批准，作为一种新疗法，使公司在未来十年内转变为一个商业可持续的运营。</p>
<p>但要为该股票做出更为乐观的投资案例，作为一种能够多倍增值的投资，将是一个更具挑战性的命题。这可能需要 Recursion 开发出一种能够在多个年度内产生数十亿美元销售额的重磅药物。</p>
<p>现实是，Recursion 距离将药物推向市场还有数年时间。目前，该公司仅通过合作里程碑付款和研究资助产生有限收入，同时面临显著更高的运营费用。华尔街分析师预计在可预见的未来将继续出现财务亏损，预计每股收益（EPS）将从今年预计的亏损 1.54 美元恶化至 2025 年的 1.65 美元。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>指标</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024（估计）</strong></td>
<td><strong>2025（估计）</strong></td>
</tr>
<tr>
<td>收入（百万美元）</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>收入变化（同比）</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>每股收益（EPS）</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS 变化（同比）</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>数据来源：Yahoo Finance。同比 = 年比年。</p>
<p>虽然市场可以基于长期增长前景忽视缺乏盈利能力，但这种动态可能会使股票承压。Recursion 的股票从 52 周高点下跌了约 55%，任何监管方面的挫折都可能使股票进一步下跌。</p>
<p>另一个考虑因素是高度竞争的行业格局。像 <strong>Merck</strong>、<strong>AstraZeneca</strong> 和 <strong>Pfizer</strong> 等主要生物科技和制药公司，越来越多地在其研发过程中使用人工智能。这种广泛的采用引发了关于 Recursion 是否能够在该领域保持技术优势的质疑。</p>
<h2>最后思考</h2>
<p>尽管 Recursion Pharmaceuticals 提供了引人注目的可能性，但我认为在对其产品批准路径没有更好可见性的情况下，现在购买该股票还为时尚早。与此同时，2025 年将是该公司提供更多关于其长期潜力的关键一年。你可能想将其保持在你的关注名单上。</p>

RXRX

<p>Recursion Pharmaceuticals 是一家利用人工智能进行药物发现的临床阶段生物技术公司，具有显著的增长潜力。其 BioHive-2 超级计算机分析生物数据以识别药物靶点，与 Exscientia 的合并增强了其能力。像 REC-994 和 REC-617 这样的有前景的药物候选者显示出潜力，但公司面临挑战，包括财务亏损和来自大型公司的竞争。分析师预测持续亏损，尽管股票具有潜力，但在没有更清晰的产品批准时间表之前，投资可能为时尚早。2025 年将是 Recursion 未来的关键年</p>

<p>Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.</p>
<div class="lb-trans"><p>成功驾驭股市需要耐心和长期的视角。关键在于坚持一致的计划，并定期向退休账户做出贡献，让复利的力量随着时间的推移发挥其魔力。</p>
</div><p>Nevertheless, there's an undeniable allure in searching for potential multibagger stocks. Something is captivating about companies with disruptive innovations, whose stocks could be on the cusp of rapid growth and capable of delivering life-changing returns to shareholders.</p>
<div class="lb-trans"><p>然而，寻找潜在的多倍收益股票无疑具有吸引力。那些拥有颠覆性创新的公司，其股票可能正处于快速增长的边缘，能够为股东带来改变生活的回报，这让人着迷。</p>
</div><p><strong>Recursion Pharmaceuticals</strong>(RXRX -0.98%) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to revolutionize medicine. Let's explore whether buying the stock could eventually help you become a millionaire.</p>
<div class="lb-trans"><p><strong>Recursion Pharmaceuticals</strong>（RXRX -0.98%）是一家临床阶段的生物科技公司，可能具备这样的潜力。该公司利用人工智能（AI）进行药物发现，承诺将彻底改变医学。让我们探讨一下购买该股票是否最终能帮助你成为百万富翁。</p>
</div><h2>AI-powered biotech</h2>
<div class="lb-trans"><h2>AI 驱动的生物科技</h2>
</div><p>Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by <strong>Nvidia</strong> AI chips, is one of the world's most powerful accelerated computing systems.</p>
<div class="lb-trans"><p>Recursion 迅速确立了自己在 AI 驱动生物科技领域的领导地位。该公司的 BioHive-2 超级计算机，采用 <strong>Nvidia</strong> AI 芯片，是全球最强大的加速计算系统之一。</p>
</div><p>Through advanced machine learning techniques, BioHive-2 analyzes vast amounts of biological data to identify drug targets, including proteins and genes involved in disease. Recursion's operating system (OS) evaluates millions of compounds to identify potential drug candidates, while also predicting drug molecule properties and optimal patient populations to enhance drug design.</p>
<div class="lb-trans"><p>通过先进的机器学习技术，BioHive-2 分析大量生物数据，以识别药物靶点，包括与疾病相关的蛋白质和基因。Recursion 的操作系统（OS）评估数百万种化合物，以识别潜在的药物候选者，同时预测药物分子的特性和最佳患者群体，以增强药物设计。</p>
</div><p>These efforts allow accelerated research on treatments across a wide range of conditions, while reducing costs compared to traditional methods.</p>
<div class="lb-trans"><p>这些努力使得对各种疾病的治疗研究得以加速，同时与传统方法相比降低了成本。</p>
</div><p>A major development for Recursion this year was its merger with Exscientia, another biotech company focused on AI-based drug discovery. Exscientia's expertise in advanced methods of chemical design complements Recursion's biology-driven approach. This combination has created a vertically integrated platform, resulting in a fundamentally stronger company.</p>
<div class="lb-trans"><p>Recursion 今年的一项重大进展是与另一家专注于基于 AI 药物发现的生物科技公司 Exscientia 的合并。Exscientia 在先进化学设计方法方面的专业知识与 Recursion 的生物驱动方法相辅相成。这一结合创造了一个垂直整合的平台，使公司在根本上更强大。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801422%2Frecusion-pharma-ai-powered-biotech-stock.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>A promising pipeline of therapeutic candidates</h2>
<div class="lb-trans"><h2>有前景的治疗候选药物管线</h2>
</div><p>The good news is that Recursion's technology has already yielded promising results, with a robust pipeline of drug candidates that now incorporates Exscientia's legacy programs.</p>
<div class="lb-trans"><p>好消息是，Recursion 的技术已经取得了令人鼓舞的成果，拥有一条强大的药物候选管线，现在还包括 Exscientia 的遗留项目。</p>
</div><p>One of the most promising prospects is REC-994, which could become the first oral therapy for treating symptomatic cerebral cavernous malformation (CCM), a brain hemorrhaging condition that currently lacks any approved treatments.</p>
<div class="lb-trans"><p>其中最有前景的候选药物之一是 REC-994，它可能成为治疗症状性脑血管畸形（CCM）的首个口服疗法，这是一种目前没有任何批准治疗的脑出血疾病。</p>
</div><p>REC-617 has also shown encouraging results, with a recent phase 1 interim study demonstrating positive patient responses and good tolerability in treating advanced solid tumors. The company believes this drug has &#34;best in class&#34; potential, one of several reasons that make Recursion an intriguing opportunity for investors.</p>
<div class="lb-trans"><p>REC-617 也显示出令人鼓舞的结果，最近的 1 期中期研究表明，在治疗晚期实体瘤方面患者反应积极且耐受性良好。公司认为该药物具有 “最佳同类” 潜力，这是使 Recursion 成为投资者引人注目的机会的几个原因之一。</p>
</div><p>Looking ahead to 2025, the market will be closely following clinical readouts and regulatory updates as catalysts for Recursion stock:</p>
<div class="lb-trans"><p>展望 2025 年，市场将密切关注临床结果和监管更新，作为 Recursion 股票的催化剂：</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801422%2Flarge-pipeline-recursion-stock-bullish-outlook-2025.png&amp;op=resize&amp;w=700"/></p>
<p>Source: Recursion Pharmaceuticals.</p>
<div class="lb-trans"><p>来源：Recursion Pharmaceuticals。</p>
</div><h2>Reasons for caution</h2>
<div class="lb-trans"><h2>谨慎的理由</h2>
</div><p>It seems likely that at least one of Recursion Pharmaceuticals' candidates could eventually gain approval as a novel therapy, transforming the company into a commercially sustainable operation over the next decade.</p>
<div class="lb-trans"><p>看起来至少有一个 Recursion Pharmaceuticals 的候选药物最终可能获得批准，作为一种新疗法，使公司在未来十年内转变为一个商业可持续的运营。</p>
</div><p>But making a much more bullish case for the stock, as an investment to multiply many times over, would be a significantly more challenging proposition. It would likely require Recursion to develop a blockbuster drug capable of generating billions of dollars in sales across multiple years.</p>
<div class="lb-trans"><p>但要为该股票做出更为乐观的投资案例，作为一种能够多倍增值的投资，将是一个更具挑战性的命题。这可能需要 Recursion 开发出一种能够在多个年度内产生数十亿美元销售额的重磅药物。</p>
</div><p>The reality is that Recursion remains years away from bringing a drug to market. Currently, the company generates only limited revenue through partnership milestone payments and research grants, while facing substantially higher operating expenses. Wall Street analysts project continued financial losses for the foreseeable future, with negative earnings per share (EPS) expected to worsen from a projected loss of $1.54 this year to $1.65 in 2025.</p>
<div class="lb-trans"><p>现实是，Recursion 距离将药物推向市场还有数年时间。目前，该公司仅通过合作里程碑付款和研究资助产生有限收入，同时面临显著更高的运营费用。华尔街分析师预计在可预见的未来将继续出现财务亏损，预计每股收益（EPS）将从今年预计的亏损 1.54 美元恶化至 2025 年的 1.65 美元。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metric</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024 (Estimate)</strong></td>
<td><strong>2025 (Estimate)</strong></td>
</tr>
<tr>
<td>Revenue (in millions)</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>Revenue change (YOY)</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>Earnings per share (EPS)</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS change (YOY)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>指标</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024（估计）</strong></td>
<td><strong>2025（估计）</strong></td>
</tr>
<tr>
<td>收入（百万美元）</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>收入变化（同比）</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>每股收益（EPS）</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS 变化（同比）</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>Data source: Yahoo Finance. YOY = year over year.</p>
<div class="lb-trans"><p>数据来源：Yahoo Finance。同比 = 年比年。</p>
</div><p>While the market can overlook a lack of profitability based on longer-term growth prospects, the dynamic may keep the stock under pressure. Shares of Recursion are down approximately 55% from their 52-week high, and any sort of regulatory setback could send the stock even lower.</p>
<div class="lb-trans"><p>虽然市场可以基于长期增长前景忽视缺乏盈利能力，但这种动态可能会使股票承压。Recursion 的股票从 52 周高点下跌了约 55%，任何监管方面的挫折都可能使股票进一步下跌。</p>
</div><p>Another consideration is the highly competitive industry landscape. Major biotech and pharmaceutical companies like <strong>Merck</strong>, <strong>AstraZeneca</strong>, and <strong>Pfizer</strong>, among others, are increasingly using artificial intelligence in their research and development processes. This widespread adoption raises questions about whether Recursion can maintain a technological advantage in the field.</p>
<div class="lb-trans"><p>另一个考虑因素是高度竞争的行业格局。像 <strong>Merck</strong>、<strong>AstraZeneca</strong> 和 <strong>Pfizer</strong> 等主要生物科技和制药公司，越来越多地在其研发过程中使用人工智能。这种广泛的采用引发了关于 Recursion 是否能够在该领域保持技术优势的质疑。</p>
</div><h2>Final thoughts</h2>
<div class="lb-trans"><h2>最后思考</h2>
</div><p>Although Recursion Pharmaceuticals offers compelling possibilities, I believe that without better visibility into its product approval pathway, it's just too early to buy this stock with conviction. In the meantime, 2025 will be a crucial year for the company to offer more clarity on its long-term potential. You may want to keep this one on your radar.</p>
<div class="lb-trans"><p>尽管 Recursion Pharmaceuticals 提供了引人注目的可能性，但我认为在对其产品批准路径没有更好可见性的情况下，现在购买该股票还为时尚早。与此同时，2025 年将是该公司提供更多关于其长期潜力的关键一年。你可能想将其保持在你的关注名单上。</p>
</div>

Recursion Pharmaceuticals 的股票能否成为百万富翁制造者？